文献速递泌尿生殖与妇科肿瘤放疗

联合Gleason评分作为接受剂量递增放疗的前列腺癌独立有利预后因素的验证

Validation of the Combination Gleason Score as an Independent Favorable Prognostic Factor in Prostate Cancer Treated With Dose-Escalated Radiation Therapy.
PubMed 文献 · Pract Radiat Oncol · 2022-10-27

在2家机构接受根治性剂量递增放疗的2539例前列腺癌患者中,687例存在联合Gleason评分(ComboGS)。在Gleason 7-10患者中,ComboGS与10年生化无事件生存、无远处转移生存、前列腺癌特异性生存和总生存改善相关,多因素分析支持其保护作用,且校正mCAPRA评分后仍降低生化失败和远处转移风险。

要点

  • 在Gleason 7-10患者中,ComboGS与10年生化无事件生存从76.6%提高至82.4%相关(HR 0.75,95%CI 0.59-0.96,P=0.021)。
  • 多因素分析支持ComboGS对生化失败、远处转移、前列腺癌死亡和总死亡的保护作用。
  • 校正ComboGS后mCAPRA评分降低生化失败风险近30%(HR 0.70,95%CI 0.55-0.88,P=0.003)和远处转移风险50%(HR 0.54,95%CI 0.37-0.80,P=0.002)。

核心结论

  • ComboGS是所有评估临床终点的有用且 readily available 的独立预后因素。
  • ComboGS可与广泛验证的CAPRA评分联合使用,以更好地对接受根治性DE-RT的Gleason 7-10疾病患者进行风险分层。

研究设计与样本

  • 在2家机构接受根治性剂量递增放疗(DE-RT)的2539例男性中,687例存在ComboGS。
  • 采用改良前列腺癌风险评估(mCAPRA)评分进一步确定ComboGS效应,比较有无修饰的CAPRA评分间的生化无事件生存率和无远处转移生存率,并使用Harrel一致性指数比较CAPRA评分的预后价值。

主要发现

  • 在Gleason 7-10患者单因素分析中,ComboGS使10年生化无事件生存率从76.6%提高至82.4%(HR 0.75,95%CI 0.59-0.96,P=0.021)。
  • 在Gleason 7-10患者单因素分析中,ComboGS使10年无远处转移生存率从89.3%提高至93.2%(HR 0.57,95%CI 0.39-0.85,P=0.005)。
  • 在Gleason 7-10患者单因素分析中,ComboGS使10年前列腺癌特异性生存率从93.9%提高至97.4%(HR 0.39,95%CI 0.21-0.7,P=0.001)。
  • 在Gleason 7-10患者单因素分析中,ComboGS使10年总生存率从65.7%提高至75.6%(HR 0.69,95%CI 0.57-0.83,P<0.001)。
  • 多因素分析支持ComboGS对生化失败(HR 0.64,95%CI 0.50-0.83,P<0.001)、远处转移(HR 0.42,95%CI 0.28-0.63,P<0.001)、前列腺癌死亡(HR 0.32,95%CI 0.17-0.58,P<0.001)和总死亡(HR 0.65,95%CI 0.54-0.79,P<0.001)具有保护作用。

关键数值与推荐

  • 校正ComboGS后mCAPRA评分降低生化失败风险近30%(HR 0.70,95%CI 0.55-0.88,P=0.003)。
  • 校正ComboGS后mCAPRA评分降低远处转移风险50%(HR 0.54,95%CI 0.37-0.80,P=0.002)。

临床怎么用

  • 原文结论指出ComboGS是所有评估临床终点的有用且 readily available 的独立预后因素。
  • 原文结论指出ComboGS可与广泛验证的CAPRA评分联合使用,以更好地对接受根治性DE-RT的Gleason 7-10疾病患者进行风险分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prognostic factors for prostate cancer include tumor, node, metastases stage, pretreatment prostate-specific antigen, and pathology (via Gleason score [GS] or grade group). Of these, GS yields the largest effect on prostate cancer specific mortality. It was previously determined that those with cores with a mix of higher and lower GS at biopsy (which was termed a "ComboGS") had decreased risk for prostate cancer specific mortality after either surgical or radiation treatment. We validate the effect of ComboGS in an independent cohort of patients with prostate cancer treated with definitive dose-escalated radiation therapy (DE-RT) at 2 institutions. METHODS AND MATERIALS: DE-RT was administered to 2539 men, of which 687 men had a ComboGS. To further ascertain the ComboGS effect we employed the modified Cancer of the Prostate Risk Assessment (mCAPRA) score. Rates of biochemical event-free survival and distant metastasis-free survival were compared across CAPRA scores, with and without modification, and the prognostic value of the CAPRA scores was compared using Harrel's concordance index. RESULTS: On univariate analysis in Gleason 7 to 10 patients the presence of ComboGS improved 10-year biochemical event-free survival from 76.6% to 82.4% (hazard ratio [HR], 0.75; confidence interval [CI], 0.59-0.96; P = .021), 10-year distant metastasis-free survival from 89.3% to 93.2% (HR, 0.57; CI, 0.39-0.85; P = .005), 10-year prostate cancer specific survival from 93.9% to 97.4% (HR, 0.39; CI, 0.21-0.7; P = .001), and 10-year overall survival from 65.7% to 75.6% (HR, 0.69; CI, 0.57-0.83; P < .001). Multivariable analysis also supported that ComboGS is protective for biochemical failure (HR, 0.64; CI, 0.50-0.83; P < .001), distant metastasis (HR, 0.42; CI, 0.28-0.63; P < .001), death from prostate cancer (HR, 0.32; CI, 0.17-0.58; P < .001), and overall mortality (HR, 0.65; CI, 0.54-0.79; P < .001). Additionally, adjusting the mCAPRA score for ComboGS decreased the risk of biochemical failure by nearly 30% (HR, 0.70; 95% CI, 0.55-0.88; P = .003) and by 50% (HR, 0.54; 95% CI, 0.37-0.80; P = .002) for distant metastasis. CONCLUSIONS: ComboGS is a useful and readily available independent prognostic factor for all clinical endpoints evaluated. Moreover, the ComboGS can be used in conjunction with the extensively validated CAPRA scoring to better risk stratify patients being treated with definitive DE-RT for GS 7 to 10 disease.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Quinn TJ, Chapman D, Parzen J, et al. Validation of the Combination Gleason Score as an Independent Favorable Prognostic Factor in Prostate Cancer Treated With Dose-Escalated Radiation Therapy. Pract Radiat Oncol. 2022. PMID: 36503624. doi:10.1016/j.prro.2022.08.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。